: Endometrial Cancer Data Sets. (A) Schematic showing data sanitization procedures for TCGA endometrial cancer data sets. Transcription sequencing data of primary tumours and normal adjacent tissues were queried and processed by TCGA-Assembler. UCEC patients' clinical data were also downloaded by TCGA-Assembler. Methylation (including available primary tumor tissues and tumor adjacent normal tissues), somatic copy number alteration (SCNA) and mutation profiles were downloaded from public TCGA database. Downloaded methylation data in data level 3 was further processed by TCGA-Assembler to calculate gene-based methylation value. (B) Principal component analysis (PCA) of 370 available expression profiles of primary tumor tissues. The first three principal components were used to assess the sample relatedness and underlying confounding factors. Based on the visualized plots, transcription profiles of endometrial cancer patients were well-clustered with no significant outlier was detected. (C) Density plots for measuring the distribution of SCNAs [bottom left], CpG methylation and residual expression data [bottom right]. CpG methylation profiles of primary tumor tissues and tumor adjacent normal tissues were illustrated separately [top left and top right]. Importantly, the distribution of residuals approximated normal distribution, and met the prerequisite for linear regression analysis to identify expression-associated single nucleotide variations. (D) Schematic showed the mutation analysis procedure. To identify significant expression-associated single nucleotide variations (eSNVs), linear regression analysis was conducted followed by Bonferroni correction. The association tests for mutation profile were SNV-based instead of gene-based. We tested the association between 5,824 somatic mutations to relative transcript level of 13,491 genes (phenotypes). As a result, 4,153 somatic mutations were identified to be expression-associated single nucleotide variant. The mutation status of these eSNVs was correlated to the expression level of 2,612 genes.
Supplementary Figure S2: Gene-based prioritization and mutation clusters identification. (A) Schematic showing genebased prioritization procedures. DawnRank algorithm was applied for identifying candidate driver genes based on protein-protein interaction information (See Materials and Methods)
. By using DawnRank algorithm, personalized driver mutations were identified and we further applied individual cut-off to select significant personalized drivers. Besides, we also included twelve TCGA mutational signatures to aid in prioritization. (B) Bar plot showed distribution of number of driver mutations identified by DawnRank. As shown, a large proportion of patients contained less than 100 drivers, while a small amount of patients carried large amount of driver mutations (200 to 300). The x-axis was somatic mutation and the y-axis was -log 10 value of p-value. SNVs were plotted individually based on their located genes. (B) Table indicated 31 eSNVs that were either cluster-related or prognostic-related. Mutations including 7:74148279 (GTF2I) and rs28934576 (TP53) showed correlation to both the identified mutational cluster and progression-free survival. (C) Consensus clustering of eSNVs based on their correlated transcripts for co-occurrence analysis. The matrix contained beta coefficients of eSNVs against genes was used for identifying eSNVs that showed similar cooperative dysregulation pattern by correlated with the expression level of the same genes. The heatmaps of the consensus matrix for k equal to 2, 3, 4, 5, 6 and 7 were showed in following manner: consensus values ranged from zero (white) to one (blue), which represented never clustered together and always clustered together, respectively. Besides, consensus cumulative distribution function (CDF) plot and Delta area plot were also constructed to aid determination of number of consensus cluster (k). We chose k = 4 as there is no appreciable relative increase in consensus after k = 4. (D) Summaries of co-occurrence results. After determine the number of consensus cluster (k = 4), the number of significant eSNV pairs belong to each cluster was calculated. 
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SUPPLEMENTARY NOTE 13 prognostic-related signatures
In 13 identified prognostic-related signatures, three (chr17:7578271, rs28934576, and rs28934874) were located in TP53. Two of the prognostic-related eSNVs (chr4:153249384 and chr4:153249510) were in FBXW7. FBXW7 is a tumor suppressor that mediates ubiquitin-dependent proteolysis of cyclin E1, c-Myc, c-Jun, and Notch in endometrial cancer [1] . In CHD4, a gene plays an important role in epigenetic transcriptional repression, somatic alteration on chr12:6701638 were detected to be correlated with survival. In addition, we also found prognostic-related somatic alterations on PIK3R1 and PTEN, which are well-known cancer drivers in endometrial cancer [2] . Also, mutations on YEATS2, an epigenetic regulator were identified to be prognosisrelated. Other identified prognosis-related signatures were located in genes that are less characterized in endometrial cancer, including OGDHL, MEGF8, MORC2, and GTF2I. OGDHL is an AKT-dependent nuclear factor (NF)-κB signaling modifier, and was suggested to act as an antiproliferative gene [3] . MEGF8 is a membrane protein gene that participates in developmental regulation and cellular communication [4] . MORC2 is mainly located in nuclei, it was reported to act as a transcriptional repressor in cancer cells, and its signaling integrates extracellular signals and nuclear processes during DNA damage [5, 6] . Lastly, the GTF2I mutation was reported to occur at high frequencies in thymic epithelial tumors [7] , suggesting an oncogenic role of GTF2I in cancer.
SNV-based somatic mutation profiles
We conducted several analyses to link gene expression levels to somatic alterations in an SNVbased manner to further consummate the explanation of mutational impacts on cancer transcriptomic profiles. First, we conducted an SNV-based linear regression test and revealed that different eSNVs in a gene may exert different effects (quantified by the β-coefficient) on the same genes' transcript levels. We use TP53 as an example: chr17:7577563 and rs121913343 were both significantly correlated with transcript levels of LAG3 and SLAMF7, but the effects differed (β-coefficient = 0.32 vs. 0.17 for LAG3 and 0.46 vs. 0.24 for SLAMF7, respectively). In addition, chr17:7578271 and chr17:7578406 also showed different effects on NLRP7 (β-coefficients = 0.50 and 0.35, respectively). Second, we classified eSNVs by consensus clustering on β-coefficients to genes and discovered that eSNVs on the same genes may be grouped into different consensus clusters based on their correlated transcript profiles. Based on these findings, we finally conducted SL pair identification by bioinformatics means in an eSNV-based fashion. We found that 129 eSNVs had potential SL to other genes. Although further validation is needed, these findings consolidate our contention that cancer-relevant somatic mutations which have SL to genes could be SNV-specific.
